Estimates of the effects of disease progression on HRQoL from mixed-effects longitudinal models for LUX-Lung 1 and LUX-Lung 3
| HRQoL measure | Independent review | Investigator assessment | ||
|---|---|---|---|---|
| Progression effect (95% CI) | p Value | Progression effect (95% CI) | p Value | |
| LUX-Lung 1 | ||||
| EORTC Global Health/QoL | −4.24 (−6.09 to −2.40) | <0.0001 | −4.65 (−6.44 to −2.87) | <0.0001 |
| EQ-5D UK Utility | −0.056 (−0.083 to −0.028) | <0.0001 | −0.065 (−0.092 to −0.039) | <0.0001 |
| EQ VAS | −3.76 (−5.19 to −2.32) | <0.0001 | −3.83 (−5.21 to −2.44) | <0.0001 |
| LUX-Lung 3 | ||||
| EORTC Global Health/QoL | −4.56 (−6.09 to −3.03) | <0.0001 | −5.62 (−7.27 to −3.96) | <0.0001 |
| EQ-5D UK Utility | −0.061 (−0.082 to −0.041) | <0.0001 | −0.076 (−0.099 to −0.054) | <0.0001 |
| EQ VAS | −3.62 (−4.79 to −2.45) | <0.0001 | −4.29 (−5.54 to −3.03) | <0.0001 |
A negative value indicates a deterioration in HRQoL associated with progression.
CI, confidence interval; EORTC, European Organization for Research and Treatment of Cancer; VAS, Visual Analogue Scale; HRQoL, health-related quality of life.